Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

taVNS reduces vitiligo symptoms in mice.

Hair follicles are normally protected from the immune system, but when this protection fails, it can cause hair loss in alopecia areata.

Stress may contribute to hair loss in alopecia areata by affecting immune responses and cell death in hair follicles.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.

A new mouse model for vitiligo helps study immune responses and potential treatments.

Sparse hairless patches can develop and stabilize in alopecia areata under certain conditions.

Mouse hair follicle stem cells can help prevent Type 1 Diabetes.

Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.

A patient with Ivemark syndrome developed mixed type vitiligo after a hepatitis C infection, showing different treatment responses and immune cell involvement in the skin.

IL-27 may help prevent hair loss by creating immune-suppressing cells.

BTNL2 helps protect hair follicles from immune attacks, which could aid in treating alopecia areata.

T-cells in alopecia areata scalp show abnormal regulation, leading to less inflammation.

Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.

Androgenetic alopecia involves immune cell disruptions, especially increased CD4+ T cells around hair follicles.

EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.

UV exposure harms skin by causing fibroblast loss, but T cells help fibroblast survival.

Poor response to topical immunotherapy in alopecia areata patients is linked to impaired cell responses.

IL-15 is key for T cell function and could help improve treatments for immune-related diseases.

Vitiligo and alopecia areata may have similar causes despite their differences.

Myeloid-derived suppressor cells help control autoimmune cells and promote hair regrowth in alopecia areata.

ILC1-like cells can cause alopecia areata by attacking hair follicles.

Mast cells and CD8 T cells interact closely in skin diseases, affecting each other's behavior and contributing to conditions like psoriasis and eczema.

CD8+ T cells are involved in alopecia areata and may cause disease relapse.

CD80CD86 deficiency causes hair loss by disrupting regulatory T cells.

Higher CD8+ T cell levels are linked to Alopecia areata in Iraqi patients.

New treatments targeting T-cell pathways are needed for better alopecia areata management.

T cells and bacteria in the gut and skin help maintain health and protect against disease.

Blocking the CXCR3 receptor reduces T cell accumulation in the skin and prevents hair loss in mice.

Hair follicles may help teach the immune system to tolerate new self-antigens, but this can sometimes cause hair loss.